Objective To evaluate the effect of salmeterol xinafoate and fluticasone propionate powder for inhalation combined with high-flow nasal cannula oxygen therapy（HFNC）on patients with AECOPD and type Ⅱ respiratory failure. Methods 110 patients with AECOPD and type Ⅱ respiratory failure were divided into observation group and control group randomly. The control group was given to HFNC, and observation group was given to salmeterol xinafoate and fluticasone propionate powder for inhalation combined with HFNC. The FEV1, FVC, FEV1/FVC, PaO2, PaCO2, SaO2, pH value, IL-17, hs-CRP, SGRQ score, mMRC score and clinical efficacy were compared. Results The lung function indexs of observation group were better than the control group（P＜0.05） Compared with the control group, the pH value, SaO2 and PaO2 were higher, and PaCO2 was lessin the observation group（P＜0.05）. The serum hs-CRP and IL-17 of observation group were less（P＜0.05） The SGRQ and mMRC score were less in observation group（P＜0.05）.The clinical effect of observation group was better than control group（P＜0.05）Conclusion Salmeterol xinafoate and fluticasone propionate powder for inhalation combined with HFNC has definite clinical effect for patients with AECOPD and type Ⅱ respiratory failure, can effectively improve lung function, respiratory function and blood gas analysis indexes, and inhibit inflammation